CompletedNCT00305422
Quetiapine or risperidone for negative symptoms and cognition in schizophrenia
About this title
Read the official source — NCT00305422Medication studyAges 18–65Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- MunichSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00305422
- Official title
Show the full official title
Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Munich
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate and Risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
